Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Indivior Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Indivior Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028850
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Other current and noncurrent liabilities | (86) | 81 |
| Net cash (used in) provided by operating activities | (9) | 75 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (20) | (5) |
| Purchases of investments in debt securities | (5) | (5) |
| Sales and maturities of debt securities | 6 | 6 |
| Net cash used in investing activities | (19) | (5) |
| Cash flows from financing activities: |
Item 1. Unaudited Condensed Financial Statements.
FAQ
- What is Indivior Pharmaceuticals, Inc.'s capex?
- Indivior Pharmaceuticals, Inc. (INDV) reported capex of $20M in Q1 2026.
- How has Indivior Pharmaceuticals, Inc.'s capex changed year-over-year?
- Indivior Pharmaceuticals, Inc.'s capex increased by 300.0% year-over-year, from $5M to $20M.
- What is the long-term trend for Indivior Pharmaceuticals, Inc.'s capex?
- Over 3 years (2022 to 2025), Indivior Pharmaceuticals, Inc.'s capex has grown at a 136.3% compound annual growth rate (CAGR), from $5M to $66M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Indivior Pharmaceuticals, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude